Skip to content
Menu

Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $476

Benzinga Newsdesk 6 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.

Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.

Read at benzinga.com